Lyme Disease Diagnostic Assay - Collection of Whole Blood

Study Purpose

The primary objective is to obtain whole blood from subjects with signs and/or symptoms of early Borrelisois. Whole blood will also be obtained from subjects with suspicion of acute Borreliosis and under medical examination for Lyme disease. In addition, whole blood will be obtained from apparently healthy subjects residing in areas endemic to Lyme disease and may also inlclude apparently healthy subjects residing in areas non-endemic to Lyme disease.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Subjects with under evaluation of Lyme Disease.

Inclusion Criteria:

Signs and symptoms of acute Lyme disease which include at least one of the following:
  • - Recent onset of fatigue.
  • - Skin rash.
  • - Fever.
  • - Muscle aches.
  • - Neck pain.
  • - Joint pain or lymphadenopathy.
Subgroup Borreliosis Subjects- restricted signs and symptoms of acute Lyme including EM Rash.
  • - Under physician or medical evaluation for acute on-set of Lyme Disease presenting with EM Rash.
  • - Detailed description of the EM rash (e.g. Itchy, painful, hot, vesicular, raised) with consent for photographic documentation is required including additional picture with ruler placing to confirming size.
  • - EM rash with the following attributes: - Size > 5 cm in diameter.
  • - Appeared 3-30 days after bite or suspected bite.
  • - Specify Location (e.g. underarm or back of knee) - Subjects with confirmed early localized or disseminated Lyme Borreliosis manifestation.
  • - Signs and symptoms (e.g. Fever, Chills/Sweats, Headache, Fatigue/Tiredness, Myalgia/Sore muscles) - The EM rash has been present <42 days.
  • - Clinical diagnosis of Lyme disease is suspected by the practitioner.
  • - Ability to provide the minimum sample volume required.

Exclusion Criteria:

  • - Subjects unable to provide informed consent.
  • - Subjects without clinical information and/or not meeting inclusion criteria.
  • - Subjects having started antibiotic treatment > 5 days before inclusion.
Healthy Subjects.

Inclusion Criteria:

  • - Apparently healthy subjects with no present fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes, e.g. flu-like symptoms.
  • - Ability to provide the minimum sample volume required.

Exclusion Criteria:

  • - ● Subjects unable to provide informed consent.
  • - Subjects without clinical information and/or not meeting inclusion criteria.
  • - Subjects with a recent diagnosis of Lyme disease, Anaplasmosis, Babesiosis, or history of known embedded tick bite which may have required 'manual extraction' NOTE: a tick just found on the subject or presence of a crawling tick is not considered a 'tick bite') - Subjects currently on antibiotic treatment.
  • - Uncontrolled HIV-infection, if known.
This is defined as an HIV-1 viral load >40 copies/mL and/or CD4+ count <500 x 106 cells/liter in the past 12 months.
  • - Active syphilis or leptospirosis, if known.
  • - Active infection with Epstein Barr Virus (mononucleosis), if known.
  • - Active infection with Cytomegalovirus (CMV), if known.
  • - Subjects with autoimmune diseases, either confirmed rheumatoid arthritis and/or other autoimmune disorders diagnosed according to the leading guidelines.
  • - Current immunomodulation mediation including >7.5 mg prednisone daily, methotrexate, and/or biologicals.
Medications such as hydroxychloroquine, sulfasalazine or NSAIDs are acceptable.
  • - Immunodeficiency, hematologic malignancies in the medical history.
- Chemotherapy during the past year

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05041595
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

DiaSorin Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Enrolling by invitation
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Lyme Disease, Healthy
Additional Details

Whole blood will be collected, and processed. Some blood will be transferred to additional tubes for further processing and aliquotting. Serum and plasma will be harvested and tested, at a later date, in a clinical performance study with approved and/or commercially available devices as well as an investigational Lyme assay. This study will be coordinated by the Sponsor.

Arms & Interventions

Arms

: Sick Cohort

Borreliosis Subjects - All comers expressing signs and symtoms consistent with suspicion of acute Borreliosis and under medical examination for Lyme disease Borreliosis subjects with an Erythema Migrans Rash (subgroup)

: Apparently Healthy

Apparently healthy subjects living in an area non-endemic for Lyme disease Apparently healthy subjects living in an area endemic for Lyme disease

Interventions

Diagnostic Test: - Lyme diagnostic assay

Serological and immunoresponse assay

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

DiaSorin Inc., Stillwater, Minnesota

Status

Address

DiaSorin Inc.

Stillwater, Minnesota, 55082